Bigger than Dolly?
By Jesse Reynolds,
Genetic Crossroads
| 06. 29. 2007
Here in the United States, political maneuverings around embryonic stem cell research made headlines throughout June. But this was little more than rehearsed political theatre, reenacting a well-known script. The Democratic-controlled Congress once again passed a bill that would have undone restrictions on the federal funding of embryonic stem cell research, but the Republican President again vetoed it. Despite last year's electoral shift in Congress, the bill's advocates are still far short of the super-majority needed to override the veto.
Though the debate remains polarized and deadlocked, supporters of President Bush's restrictions - including many Republicans up for reelection next year - are no doubt looking for ways to extricate themselves from their increasingly unpopular position. To date, they've largely gambled on the emergence of alternative sources of stem cells that are just as powerful as those derived from embryos, but that can be produced without destroying embryos.
Until now, this strategy has been largely rhetorical. But it appears that scientific developments - including one that was heralded by several researchers as being as important as the birth of Dolly...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...